- Home
- INCY vs SUI Comparison
INCY vs SUI Comparison
Compare INCY & SUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INCY
- SUI
- Stock Information
- Founded
- INCY 1991
- SUI 1975
- Country
- INCY United States
- SUI United States
- Employees
- INCY N/A
- SUI N/A
- Industry
- INCY Biotechnology: Commercial Physical & Biological Resarch
- SUI Real Estate Investment Trusts
- Sector
- INCY Health Care
- SUI Real Estate
- Exchange
- INCY Nasdaq
- SUI Nasdaq
- Market Cap
- INCY 14.2B
- SUI 15.9B
- IPO Year
- INCY 1993
- SUI 1993
- Fundamental
- Price
- INCY $75.23
- SUI $127.62
- Analyst Decision
- INCY Buy
- SUI Hold
- Analyst Count
- INCY 20
- SUI 11
- Target Price
- INCY $75.12
- SUI $134.55
- AVG Volume (30 Days)
- INCY 1.3M
- SUI 817.2K
- Earning Date
- INCY 02-10-2025
- SUI 02-18-2025
- Dividend Yield
- INCY N/A
- SUI 2.98%
- EPS Growth
- INCY N/A
- SUI N/A
- EPS
- INCY 0.15
- SUI 1.87
- Revenue
- INCY $4,075,860,000.00
- SUI $3,185,600,000.00
- Revenue This Year
- INCY $16.00
- SUI N/A
- Revenue Next Year
- INCY $10.47
- SUI $2.13
- P/E Ratio
- INCY $499.49
- SUI $67.57
- Revenue Growth
- INCY 12.94
- SUI 2.14
- 52 Week Low
- INCY $50.35
- SUI $110.98
- 52 Week High
- INCY $83.95
- SUI $147.83
- Technical
- Relative Strength Index (RSI)
- INCY 59.31
- SUI 53.10
- Support Level
- INCY $72.60
- SUI $123.10
- Resistance Level
- INCY $75.18
- SUI $127.92
- Average True Range (ATR)
- INCY 1.72
- SUI 3.40
- MACD
- INCY 0.18
- SUI 0.18
- Stochastic Oscillator
- INCY 74.33
- SUI 56.96
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
About SUI Sun Communities Inc.
Sun Communities is a residential REIT that focuses on owning manufactured housing, residential vehicle communities, and marinas. The company currently owns a portfolio of 666 properties, which includes 350 manufactured housing communities, 179 residential vehicle communities, and 137 marina properties. Sun targets owning properties that are desirable as second homes or vacation properties with nearly 50% of the portfolio located in either Florida or Michigan near major bodies of water.